CHDR and Ardena celebrate 15 years of collaboration in early phase drug development

Over the past 15 years, CHDR and Ardena have developed an integrated way of working across CHDR’s early clinical operations in Leiden and Ardena’s bioanalytical laboratories in Assen and Oss. Close alignment in study design, sample logistics and reporting allows biological samples to be analysed within narrow stability windows, with results often available within days of collection.

This approach is particularly relevant for early phase studies involving complex pharmacodynamic readouts or time‑sensitive biomarkers. By aligning clinical protocols with assay requirements early on, the collaboration supports informed decision making at the transition from preclinical research to clinical development.

A recent example is an ongoing Phase 1 programme conducted with Vanqua Bio, a US‑based clinical‑stage pharmaceutical company developing therapies for neurodegenerative diseases. In this study, rapid processing and analysis of live‑cell samples were essential to reliably assess pharmacodynamic activity.

“Our collaboration with Ardena reflects how closely clinical pharmacology and bioanalysis need to work together in early phase development,” says Geert Jan Groeneveld, CEO of CHDR. “By operating as one coordinated team, we enable efficient studies and generate high‑quality data that supports informed decision making.”

The long‑standing collaboration between CHDR and Ardena continues to support early phase programmes where speed, scientific rigour and data integrity are critical.

Read the full press release on Ardena’s website: Ardena and CHDR Mark 15 Years of Strategic Partnership in Early Phase Drug Development  - Ardena